145 related articles for article (PubMed ID: 37218491)
1. Global research trends in non-alcoholic fatty liver disease.
Putri WA; Setiawan J; Sofyantoro F; Priyono DS; Septriani NI; Mafiroh WU; Yano Y; Wasityastuti W
Bratisl Lek Listy; 2023; 124(8):590-598. PubMed ID: 37218491
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
Wong CR; Nguyen MH; Lim JK
World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease.
Powell EE; Wong VW; Rinella M
Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
5. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
Tovoli F; Ferri S; Piscaglia F
Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
[TBL] [Abstract][Full Text] [Related]
7. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
Huang W; Zhang XX
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):157-160. PubMed ID: 28297806
[TBL] [Abstract][Full Text] [Related]
8. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
10. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Non-alcoholic Fatty Liver Disease in North America.
Arshad T; Golabi P; Henry L; Younossi ZM
Curr Pharm Des; 2020; 26(10):993-997. PubMed ID: 32124690
[TBL] [Abstract][Full Text] [Related]
12. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
[TBL] [Abstract][Full Text] [Related]
13. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
14. Serum butyrylcholinesterase activities in patients with non-alcoholic fatty liver disease. Comparison with liver proteosynthetic function and liver fibrosis.
Turecky L; Kupcova V; Durfinova M; Uhlikova E
Bratisl Lek Listy; 2021; 122(10):689-694. PubMed ID: 34570568
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.
Yin X; Guo X; Liu Z; Wang J
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769165
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).
Paik JM; Eberly KE; Kabbara K; Harring M; Younossi Y; Henry L; Verma M; Younossi ZM
Ann Hepatol; 2023; 28(4):101108. PubMed ID: 37088421
[TBL] [Abstract][Full Text] [Related]
17. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
Johnston MP; Patel J; Byrne CD
Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
[TBL] [Abstract][Full Text] [Related]
19. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.
Kechagias S; Ekstedt M; Simonsson C; Nasr P
Hormones (Athens); 2022 Sep; 21(3):349-368. PubMed ID: 35661987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]